Alzinova and CRST to cooperate in bringing Alzheimer’s vaccine ALZ-101 to clinical phase
Alzinova AB and Clinical Research Services Turku Oy (CRST) have initiated a cooperation to prepare Alzinova’s Alzheimer’s vaccine, ALZ-101, for the first in man clinical trial.
The joint project will review pre-clinical and scientific documentation and finalize a clinical study protocol for the vaccine. Both companies will also together seek scientific advice with the relevant regulatory authorities. The aim is to submit a clinical trial application for ethical and regulatory approval by the end of 2017.
“We are very happy to now advance into the next phase in our mission to develop a disease modifying treatment for Alzheimer’s. We are also very happy to be able to do this together with CRST, who has successfully managed a number of similar trials within Alzheimer’s before. Their knowledge and solid expertise give us a great advantage as we now move into the first detailed steps towards the clinic. We are also very glad that we can start these procedures in good time, so that our goal of moving into clinical phase in 2018 can be reached,”says Per Wester, the CEO of Alzinova.
“We are glad to be able to cooperate with Alzinova in this interesting project. Collaboration in Nordic countries works well and is very interesting with high quality professionals like people at Alzinova,” says Antti Iitiä, Managing Director of CRST Oy.
About CRST Oy
Clinical Research Services Turku – CRST Oy is a Finnish contract research organization (CRO) with over 20 years of experience of clinical trials. CRST Oy is run by experienced specialists with in-depth understanding of basic and clinical pharmacology and drug development, including clinical trial management. CRST’s core expertise lies in the understanding of disease mechanisms. Specialists from different fields participate in CRST’s operations as principal investigators and scientific consultants. CRST’s clients include many leading Finnish, Nordic and multinational Pharma companies. CRST’s services comprise clinical study design, study conduct and reporting, and regulatory affairs.